Cardiovascular company CorMatrix Cardiovascular Inc revealed on Tuesday that it has received US FDA 510(k) market clearance for the Cor PATCH for epicardial tissue support and repair in adult patients.
The company added that the Cor PATCH epicardial patch is the first epicardial cardiovascular medical device that is composed of US FDA approved first next generation CorMatrix ECM for the US cardiac surgery market.
According to the company, the Cor PATCH is used for the epicardial support and repair of atria and/or the right and left ventricular walls of the heart that have been thinned or damaged as a result of myocardial infarct.
In addition, the Cor PATCH is first in a series of products to address clinical challenges in the cardiovascular disease market, to include regenerative and innovative design solutions for congestive heart failure, and adult or paediatric cardiac valve patients, concluded the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT